Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

Pages

15 results
6:14 PM, Oct 05, 2018  |  BioCentury | Finance

Large cap comeback

progression or unacceptable toxicity Roche (SIX:ROG; OTCQX:RHHBY) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) China approves Alecensa
alectinib as monotherapy to treat anaplastic lymphoma kinase (ALK)-positive advanced NSCLC Sanofi (Euronext:SAN; NYSE:SNY) EC approves …
1:17 PM, Sep 07, 2018  |  BioCentury | Strategy

Thinking beyond Bi

since been approved -- Lynparza olaparib for ovarian cancer from AstraZeneca plc and Merck, and Alecensa
alectinib for non-small cell lung cancer (NSCLC) from Roche. On Aug. 22, China awarded its first …
2:52 PM, Jul 13, 2018  |  BioCentury | Strategy

Roche’s partnering priority

Ocrevus ocrelizumab, and assuming full year sales of four times the 1Q18 revenue of Tecentriq, Alecensa
alectinib and Venclexta venetoclax -- which are among the company’s named growth drivers -- the combined …
a crowded market, but is showing some positive signs. The anaplastic lymphoma kinase (ALK) inhibitor Alecensa
8:35 AM, Mar 09, 2018  |  BioCentury | Strategy

Accelerating Flatiron

turn was used as an active control arm compared to Phase II data for Roche’s Alecensa
alectinib. The real-world control cohort included all 75 patients in the Flatiron database who had confirmed …
4:10 PM, Oct 06, 2017  |  BioCentury | Finance

Coasting on catalysts

and Co. (NYSE:LLY) Galcanezumab Prevent migraine Submit BLA 4Q17 Genentech Inc. / Roche (SIX:ROG; OTCQX:RHHBY) Alecensa
alectinib Anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic NSCLC PDUFA date 11/30/17 Genentech Inc …
8:26 PM, Jun 02, 2017  |  BioCentury | Product Development

Leading with lung

EGFR4 . The other will present data from a Phase III study of Roche ’s Alecensa
alectinib vs. Pfizer’s Xalkori crizotinib in first-line anaplastic lymphoma kinase (ALK)-positive NSCLC. Xalkori is a dual …
inhibitor of c-Met receptor tyrosine kinase (c-MET; MET; HGFR) and ALK, and Alecensa is an ALK …
4:55 PM, Apr 28, 2017  |  BioCentury | Politics, Policy & Law

Access and innovation in Japan

Nordisk A/S (CSE:NOVOB B; NYSE:NVO) Tresiba insulin degludec Type II diabetes 9/28/12 Roche (SIX:ROG; OTCQX:RHHBY) Alecensa
alectinib (B) Non-small cell lung cancer (NSCLC) 7/4/14 Sanofi (Euronext:SAN; NYSE:SNY) Apleway tofogliflozin (C) Type II …
3:45 PM, Apr 07, 2017  |  BioCentury | Finance

To market, to market

PDUFA date 6/26/17 Genentech Inc. / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Roche (SIX:ROG; OTCQX:RHHBY) Alecensa
alectinib Anaplastic lymphoma kinase (ALK)-positive NSCLC Ph III ALEX data 2Q17 Genmab A/S (CSE:GEN) / Johnson …
6:02 PM, Jan 13, 2017  |  BioCentury | Strategy

Solidifying Takeda’s position

FDA granted accelerated approval for Zykadia in the indication in April 2014. The approval of Alecensa
alectinib from the Genentech Inc. unit of Roche was based on two Phase II trials that …
showed an ORR of 38-48%. Alecensa’s label doesn’t include PFS data, but it does note in …
4:53 PM, Dec 30, 2016  |  BioCentury | Finance

Delivering takeouts

U.S. CHF30 ($31) Genentech Inc. / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Roche (SIX:ROG; OTCQX:RHHBY) Alecensa
alectinib Anaplastic lymphoma kinase (ALK)-positive NSCLC U.S. (Japan in 2014) CHF122 ($126) Genmab A/S (CSE:GEN …

Pages